JP Morgan Chase’s Soleno Therapeutics SLNO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-51,480
| Closed | -$1.57M | – | 8046 |
|
|
2026
Q1 | $1.57M | Sell |
51,480
-64,037
| -55% | -$2.51M | ﹤0.01% | 4283 |
|
|
2025
Q4 | $5.35M | Sell |
115,517
-291,927
| -72% | -$16M | ﹤0.01% | 3245 |
|
|
2025
Q3 | $27.5M | Buy |
407,444
+148,479
| +57% | +$11M | ﹤0.01% | 1840 |
|
|
2025
Q2 | $21.7M | Buy |
258,965
+231,579
| +846% | +$17.3M | ﹤0.01% | 1899 |
|
|
2025
Q1 | $1.96M | Buy |
27,386
+3,662
| +15% | +$178K | ﹤0.01% | 3880 |
|
|
2024
Q4 | $1.07M | Buy |
23,724
+9,809
| +70% | +$508K | ﹤0.01% | 4589 |
|
|
2024
Q3 | $703K | Buy |
13,915
+3,666
| +36% | +$176K | ﹤0.01% | 4695 |
|
|
2024
Q2 | $418K | Buy |
10,249
+9,301
| +981% | +$394K | ﹤0.01% | 4781 |
|
|
2024
Q1 | $40.6K | Buy |
948
+267
| +39% | +$12.1K | ﹤0.01% | 6013 |
|
|
2023
Q4 | $27.4K | Sell |
681
-32,495
| -98% | -$924K | ﹤0.01% | 6178 |
|
|
2023
Q3 | $979K | Buy |
33,176
+33,170
| +552,833% | +$201K | ﹤0.01% | 4082 |
|
|
2023
Q2 | $26 | Sell |
6
-69,869
| -100% | -$300K | ﹤0.01% | 6776 |
|
|
2023
Q1 | $150K | Buy |
69,875
+69,869
| +1,164,483% | +$157K | ﹤0.01% | 5233 |
|
|
2022
Q4 | $0 | Sell |
6
-4
| -40% | -$5 | ﹤0.01% | 6955 |
|
|
2022
Q3 | $0 | Buy |
10
+4
| +67% | +$10 | ﹤0.01% | 6816 |
|
|
2022
Q2 | $0 | Sell |
6
-101
| -94% | -$280 | ﹤0.01% | 6849 |
|
|
2022
Q1 | $0 | Buy |
107
+101
| +1,683% | +$523 | ﹤0.01% | 6972 |
|
|
2021
Q4 | $0 | Hold |
6
| – | – | ﹤0.01% | 6932 |
|
|
2021
Q3 | $0 | Sell |
6
-195
| -97% | -$2.72K | ﹤0.01% | 6765 |
|
|
2021
Q2 | $3K | Sell |
201
-10,870
| -98% | -$184K | ﹤0.01% | 6184 |
|
|
2021
Q1 | $209K | Buy |
11,071
+551
| +5% | +$17.8K | ﹤0.01% | 5128 |
|
|
2020
Q4 | $305K | Buy |
10,520
+7,742
| +279% | +$223K | ﹤0.01% | 4648 |
|
|
2020
Q3 | $86K | Buy |
2,778
+937
| +51% | +$27.4K | ﹤0.01% | 4761 |
|
|
2020
Q2 | $61K | Buy |
+1,841
| New | +$79.8K | ﹤0.01% | 4764 |
|
|
2018
Q1 | – | Sell |
-60
| Closed | -$2K | – | 5608 |
|
|
2017
Q4 | $2K | Buy |
+60
| New | +$1.73K | ﹤0.01% | 5373 |
|
JP Morgan Chase's SLNO Position: Q2 2026 in Review
JP Morgan Chase sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 51,480 shares — an estimated $1.57M sold.
JP Morgan Chase first reported a position in SLNO in Q4 2017 and held it in 25 quarters. The position peaked at $27.5M in Q3 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.
- JP Morgan Chase reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
- JP Morgan Chase sold 51,480 Soleno Therapeutics shares in Q2 2026, an estimated $1.57M.
- JP Morgan Chase first reported a position in Soleno Therapeutics in Q4 2017 and held it in 25 quarters.
- JP Morgan Chase's Soleno Therapeutics position peaked at $27.5M in Q3 2025.
- 0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.
Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.